logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2020 – Prolonged survival with alpelisib+fulvestrant in HR+/HER2- advanced breast cancer with PI3K-pathway hyperactivation

In patients with advanced breast cancer, targetting PIK3CA-mutations with the specific inhibitor alpelisib extends survival by 8 months.